Kosel Medical Acquires Baiquantong to Strengthen Peripheral Vascular Portfolio; Medtronic Partners with Karl Storz and Pentax Renews Collaboration with Fujifilm

Over the past week, global leaders in the medical device industry have taken intensive actions, with giants strengthening collaborations, continuously expanding business boundaries, and accelerating technological iteration and upgrades. Overseas,Medtronic Secures ENT Device Partnership, Expands Surgical Robot Indications, and Enters Cardiac Ultrasound Market；Pentax and FujifilmRenewal of Endoscopic Ultrasound Cooperation to Jointly Tackle Next-Generation Endoscopic Ultrasound Technology;GE HealthCareSecured FDA approval for AI-powered products.

The domestic industry is equally active,Kossel Acquires Baiquantong,Strengthen the peripheral intervention portfolio;WDMLed the approval of a municipal key laboratory,SPHEstablish a new medical equipment leasing company through capital contribution,Sansure BiotechCapital Increase to Expand into Drug Susceptibility Testing,MindrayExecutives also implemented shareholding increases.

The details are outlined as follows:

1. Medtronic Partners with KARL STORZ

June 4, 2026Medtronic Announces Strategic Partnership with KARL STORZ, further enriching the available supply of integrated ENT surgical solutions for patients in the United States. Leveraging its AiBLE™ intelligent ENT diagnosis and treatment ecosystem, Medtronic is advancing the implementation and upgrade of sinus care towards an interconnected, intelligent diagnostic and therapeutic model.

This collaboration integrates Medtronic’s comprehensive portfolio of sinus surgery diagnostic and therapeutic products—including the StealthAXiS™ ENT surgical navigation system, which is FDA-approved for marketing in the United States—with KARL STORZ’s industry-leading endoscopic instruments and imaging systems. The two parties will launch integrated, complementary product portfolios to help streamline the entire process of equipment selection, procurement, and implementation in ENT operating rooms across the United States.

2. Pentax and Fujifilm Renew Strategic Partnership for Endoscopic Ultrasound

On June 4, Pentax officially announced the renewal of its long-term cooperation agreement with Fujifilm on endoscopic ultrasound (EUS) technology. The cooperation agreement officially took effect in April, establishing a collaborative framework to solidify the long-term partnership between the two companies.Both parties plan to continuously strengthen the supply guarantee for ultrasound diagnostic equipment and related products.

Pentax stated that the products of this collaborationCovers the Fujifilm ARIETTA 850, ARIETTA 750, and ARIETTA 65 ultrasound diagnostic systems. The equipment can be used in combination with Pentax EUS-J10 and EB-J10 series endoscopic ultrasound scopes and Inspira image processing hosts.. The comprehensive solution delivers superior image quality, precise diagnostic and therapeutic capabilities, and clinical applicability for endoscopic ultrasound procedures.

Pentax and Fujifilm Join Forces to Tackle Next-Generation Endoscopic Ultrasound Technology, Driving Technological Iteration and Upgrades in the EUS Diagnosis and Treatment Industry

3. Medtronic Submits 510(k) Application to Expand Indications for the Hugo™ Robotic Surgery System in General Surgery and Gynecology in the United States

On June 3, Medtronic announced several significant advancements, furtherExpanding the Clinical Indications for the Hugo™ Robotic-Assisted Surgery (RAS) System in the United States, to boost the development of the surgical industry.

Summary of Key Progress

· General Surgery Indications (Including Hernia Repair): 510(k) Marketing Application Submitted

·Embrace Gynecological IDE Clinical Trial: Enrollment of All Subjects Completed

·Indications for Gynecological Surgery: 510(k) Premarket Notification Submitted

·LigaSure™ RAS Maryland Surgical Instrument: 510(k) Submission to the FDA

·ProGrip™ Advanced Mesh (Specifically for Robotic Abdominal Wall Hernia Repair): FDA 510(k) Cleared

The submission of the 510(k) application for general surgery and gynecology indications will significantly expand the clinical application scope of the Hugo platform in the United States, meeting the growing clinical demand for robotic minimally invasive procedures in these two high-volume surgical specialties.

4. Medtronic Makes Strategic Investments in Two Private Companies Focused on the Development of Intracardiac Echocardiography (ICE) Catheters

On June 3, Medtronic announcedStrategic investments in two private companies specializing in the R&D of intracardiac echocardiography (ICE) catheters. Intracardiac echocardiography (ICE) catheters enable real-time, high-definition cardiac imaging during electrophysiology procedures for arrhythmias such as atrial fibrillation. Medtronic plans to integrate ICE technology into the Affera™ Mapping and Ablation System, further strengthening the differentiated competitive advantages of the Affera product ecosystem.

This investment further accelerates the development of Medtronic’s cardiac ablation business. The investment targets include two companies: Beluga Medical, a developer of next-generation intracardiac echocardiography (ICE) devices headquartered in California, USA, with products still in the pre-market R&D stage; and CardioACC, registered in Shenzhen, China, whose products have achieved early-stage commercialization. CardioACC’s self-developed ICE system received market approval from the National Medical Products Administration of China in 2025.

5. GE Healthcare’s AI-powered radiotherapy technology receives FDA approval

On June 4, GE Healthcare announced that itsMIM Contour ProtégéAI+ Version 2.0 Software Receives U.S. FDA 510(k) Clearance for Market Launch.

This AI-powered automatic contouring software is designed to assist radiation oncology teams in developing radiotherapy plans, aiming to reduce the time required for target volume delineation and allowing clinical staff to devote more attention to timely, personalized cancer diagnosis and treatment.

The company disclosed in its press release,This FDA approval is accompanied by a Predetermined Change Control Plan (PCCP), which establishes a compliance framework for subsequent product algorithm iterations and feature upgrades.GE Healthcare plans to leverage this mechanism to continuously expand its AI models, adapting them to a wider range of human anatomical regions and various imaging modalities.

According to GE HealthCare, target volume delineation is a critical step in radiotherapy planning that accounts for a significant proportion of the time required. Artificial intelligence solutions can substantially improve the efficiency of this process while ensuring delineation accuracy. Compared with traditional automatic delineation tools, MIM Contour ProtégéAI+2.0 requires minimal manual intervention: the system automatically initiates contouring, fully processes CT and MR images, and allows the delineation results to be directly imported into radiotherapy planning systems or the MIM software workflow.

2. SPH and Others Establish New Company with Registered Capital of RMB 800 Million

According to Tianyancha, Shanghai Pharmaceuticals Yiyao (Shanghai) Co., Ltd. was recently established, with Gu Bin as its legal representative and a registered capital of RMB 800 million. Its business scope includes:Leasing of Class I medical devices; Leasing of mechanical equipment; Warehousing equipment leasing services; exhibition and display services for digital creative products, etc. Equity penetration data from Qichacha shows that the company is jointly held by Shanghai Pharmaceuticals Holdings Co., Ltd., a wholly-owned subsidiary of SPH, and Shanghai Pharmaceuticals Big Health Cloud Commerce Co., Ltd.

3. Mindray Medical Executive Li Chaoyang Increases Holdings by 5,000 Shares at a Cost of RMB 723,900

On June 3, 2026, Li Chaoyang, Deputy General Manager of Mindray Medical, increased his shareholding by 5,000 shares through competitive bidding, accounting for 3.57% of his total holdings. The transaction amounted to RMB 723,900. As of now, Li Chaoyang holds 140,000 shares, representing 0.01% of the total share capital. According to the 2025 annual report, Li Chaoyang’s minimum compensation was RMB 5.5731 million.

4. Sansure Biotech Invests RMB 35 Million in Capital Increase of Shengwei Sumin, Doubling Down on the Rapid Antimicrobial Susceptibility Testing Sector

On June 4, Sansure Biotech issued an announcement stating that, to further improve the company’s strategic layout in the field of rapid antimicrobial susceptibility testing and enhance industrial synergies, the company plans to jointly increase capital with related parties, including the Sansure Jin Furong Fund, and other investors.Hunan Shengwei Sumin Biotechnology Co., Ltd.Among them, the Company intends to contribute RMB 35 million to subscribe for the newly increased registered capital of the target company, Shengwei Sumin, amounting to RMB 31.818182 million. The Sansure Jinfurong Fund intends to invest an amount consistent with that of the Company.

5. Midea Healthcare Approved for Beijing Key Laboratory, Tackling “Liquid-Helium-Free MRI + Ultra-Wide-Bore Ultra-High-Speed CT”

Recently, by Midea Healthcare's subsidiaryWDM Leads, jointly with Zhongke Magnetic Control, Beijing Friendship Hospital of Capital Medical University, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, and Beijing Tiantan Hospital of Capital Medical University to jointly apply for the “Beijing Key Laboratory for Innovation and Translation of Advanced Superconducting Magnetic Resonance and Computed Tomography Medical Equipment”, officially approved and recognized by the Beijing Municipal Science & Technology Commission and the Zhongguancun Administrative Committee.

The laboratory is strategically positioned to address core challenges in the field of high-end medical imaging equipment, focusing primarily on helium-free superconducting magnetic resonance imaging (MRI) and ultra-wide-body, ultra-high-speed computed tomography (CT). It conducts concentrated research and development on key technologies, including helium-free magnet integration, non-contact cardiovascular gating, AI-driven scan positioning and reconstruction, precision mounting of ultra-wide-body detectors, X-ray tube manufacturing, and high-power high-voltage generator inversion. The goal is to develop high-end imaging equipment with fully independent intellectual property rights and achieve its industrialization.

END